Morningstar

Coloplast AS ADR CLPBY

Morningstar Rating
Unlock
Stock PINX Rating as of
$13.02 −0.03 (0.23%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Coloplast: Stays a Step Ahead of Competition Thanks to Innovative New Products

Debbie S. Wang

Though inflationary pressures have been alleviated to some extent, Coloplast’s ongoing launches of key new products should damp operating margin until fiscal 2026. After taking another look at how these product introductions are going, we’re leaving our fair value estimate intact. Despite the incremental investment needed to support the commercialization of these new products, we think Coloplast’s advances in ostomy, continence care, and advanced wound technologies reinforce the foundation of the firm’s wide economic moat.

Read Full Report

Price vs Fair Value

View History
CLPBY is trading within a range we consider fairly valued.
Price
$13.02
Fair Value
$36.50
Uncertainty
Medium
1-Star Price
$98.61
5-Star Price
$6.17
Economic Moat
Myptp
Capital Allocation
Klxjwfnbj

Bulls Say, Bears Say

Bulls

Because of aging populations in developed countries, the incidence of colorectal disease is growing. Independent of age, the incidence of inflammatory bowel disease is also on the rise.

Bears

Now that Coloplast has already shifted most of its manufacturing to low-cost geographies, gains in gross margin may not be so easy to achieve.

Show More

Trading Information

Previous Close Price
$13.05
Day Range
$12.90–13.03
52-Week Range
$9.90–14.34
Bid/Ask
$12.95 / $14.20
Market Cap
$29.30 Bil
Volume/Avg
39,679 / 54,794

Key Statistics

Price/Earnings (Normalized)
40.33
Price/Sales
7.67
Dividend Yield (Trailing)
2.33%
Dividend Yield (Forward)
2.33%
Total Yield
2.33%

Company Profile

Coloplast AS is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Growth
Total Number of Employees
16,019
Website
https://www.coloplast.com

Competitors

Valuation

View More
Metric
CLPBY
BSX
CTEC
Price/Earnings (Normalized)
 40.3337.8918.50
Price/Book Value
 12.356.103.53
Price/Sales
 7.678.212.66
Price/Cash Flow
 58.7331.6916.97
Price/Earnings
CLPBY
BSX
CTEC

Financial Strength

Metric
CLPBY
BSX
CTEC
Quick Ratio
 0.530.951.21
Current Ratio
 0.851.612.26
Interest Coverage
 8.818.663.44
Quick Ratio
CLPBY
BSX
CTEC

Profitability

Metric
CLPBY
BSX
CTEC
Return on Assets (Normalized)
 11.10%9.33%7.42%
Return on Equity (Normalized)
 35.43%17.03%16.55%
Return on Invested Capital (Normalized)
 15.15%11.85%10.83%
Return on Assets
CLPBY
BSX
CTEC

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
DkvlkmtwJqtkj$172.9 Bil
 Becton Dickinson & Co
BDX
SbdtqrxZmjtvm$69.3 Bil
 Alcon Inc
ALC
ZsqftfbzHryhdm$49.2 Bil
 ResMed Inc
RMD
VjmtxnqgbHgcxps$35.1 Bil
 West Pharmaceutical Services Inc
WST
GkqprgzzVyfb$21.7 Bil
 The Cooper Companies Inc
COO
RvclcrfhbHbdwxv$21.5 Bil
 Hologic Inc
HOLX
CbpkhhzJddxfq$18.5 Bil
 Baxter International Inc
BAX
SfxlxbzzHnwrtw$18.4 Bil
 Align Technology Inc
ALGN
WpbrcnqjqNwbdhl$17.8 Bil

Sponsor Center